Zoetis Inc. (NYSE:ZTS) Stock Has Consensus Price Target of $101.08 According to Analysts

Zoetis Inc. (NYSE:ZTS) has received an average recommendation of “Hold” from the nineteen ratings firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $101.08.

Several equities research analysts have issued reports on the stock. Piper Sandler decreased their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. BNP Paribas Exane cut their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research note on Thursday, August 20th. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a research report on Tuesday, August 25th. Finally, UBS Group lowered their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th.

Zoetis Stock Up 2.5%

Shares of NYSE:ZTS opened at $71.41 on Thursday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company has a market capitalization of $29.51 billion, a P/E ratio of 11.76, a P/E/G ratio of 1.63 and a beta of 0.74. Zoetis has a 52-week low of $68.77 and a 52-week high of $148.30. The stock’s fifty day simple moving average is $74.28 and its 200-day simple moving average is $85.86.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the business posted $1.76 EPS. The firm’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts forecast that Zoetis will post 6.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zoetis

Several hedge funds have recently made changes to their positions in ZTS. Physician Wealth Advisors Inc. lifted its stake in Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after buying an additional 91 shares during the last quarter. Brown Lisle Cummings Inc. grew its position in shares of Zoetis by 6.3% during the first quarter. Brown Lisle Cummings Inc. now owns 1,621 shares of the company’s stock worth $192,000 after acquiring an additional 96 shares during the last quarter. Lipe & Dalton increased its holdings in shares of Zoetis by 2.2% in the 1st quarter. Lipe & Dalton now owns 4,698 shares of the company’s stock valued at $555,000 after acquiring an additional 102 shares during the period. Riverwater Partners LLC increased its holdings in shares of Zoetis by 3.6% in the 4th quarter. Riverwater Partners LLC now owns 2,949 shares of the company’s stock valued at $371,000 after acquiring an additional 103 shares during the period. Finally, Root Financial Partners LLC raised its position in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.